Study identifier:D0850C00015
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A phase I open-labeled, fixed sequence study to determine the effect of multiple doses of AZD6280 on the pharmacokinetics of midazolam (CYP3A4) and caffeine (CYP1A2)
Healthy
Phase 1
Yes
AZD6280, Midazolam, Caffeine
Male
24
Interventional
18 Years - 45 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The aim of this study is to investigate the effects of taking repeated doses of AZD6280 on the blood levels of midazolam and caffeine in healthy volunteers
Location
Location
London, United Kingdom
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: AZD6280 oral Drug: Midazolam oral Drug: Caffeine oral |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.